The Rosacea drugs in development market research report provides comprehensive information on the therapeutics under development for Rosacea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Rosacea. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Rosacea and features dormant and discontinued products.
GlobalData tracks 21 drugs in development for Rosacea by 21 companies/universities/institutes. The top development phase for Rosacea is phase ii with 11 drugs in that stage. The Rosacea pipeline has 21 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Rosacea pipeline products market are: Amgen, Maruho and Pfizer.
The key targets in the Rosacea pipeline products market include 16S Ribosomal RNA (16S rRNA), 26s Proteasome , and Acetylcholinesterase (Acetylcholine Hydrolase or Yt Blood Group or Apoptosis Related Acetylcholinesterase or ACHE or EC 3.1.1.7).
The key mechanisms of action in the Rosacea pipeline product include 16S Ribosomal RNA (16S rRNA) Inhibitor with two drugs in Phase III. The Rosacea pipeline products include seven routes of administration with the top ROA being Topical and four key molecule types in the Rosacea pipeline products market including Small Molecule, and Monoclonal Antibody.
Rosacea overview
Rosacea is a chronic and potentially life-disruptive disorder primarily of the facial skin, often characterized by flare-ups and remissions. Symptoms include frequent redness of the face, or flushing; small red lines under the skin; a swollen nose; and thick skin, usually on the forehead, chin, and cheeks. The predisposing factors include age and family history of rosacea. Treatment includes antibiotics and acne drugs.
For a complete picture of Rosacea’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
